Balentine LLC’s Ionis Pharmaceuticals IONS Stock Holding History

Balentine LLC’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-845	Closed	-$50K	–	501
2020 Q2	$50K	Buy	845 +239	+39%	+$13.3K	﹤0.01%	242
2020 Q1	$29K	Hold	606	–	–	﹤0.01%	230
2019 Q4	$37K	Hold	606	–	–	﹤0.01%	230
2019 Q3	$36K	Hold	606	–	–	﹤0.01%	168
2019 Q2	$39K	Hold	606	–	–	﹤0.01%	130
2019 Q1	$49K	Hold	606	–	–	﹤0.01%	120
2018 Q4	$33K	Hold	606	–	–	﹤0.01%	140
2018 Q3	$31K	Buy	+606	New	+$28.5K	﹤0.01%	101
2018 Q1	–	Sell	-1,544	Closed	-$78K	–	279
2017 Q4	$78K	Hold	1,544	–	–	0.01%	222
2017 Q3	$78K	Sell	1,544 -172	-10%	-$9.01K	0.01%	213
2017 Q2	$87K	Hold	1,716	–	–	0.01%	185
2017 Q1	$69K	Hold	1,716	–	–	0.01%	198
2016 Q4	$82K	Buy	1,716 +509	+42%	+$20.1K	0.01%	164
2016 Q3	$44K	Buy	+1,207	New	+$37.8K	0.01%	184

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Balentine LLC's IONS Position: Q3 2020 in Review

Balentine LLC sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 845 shares — an estimated $50K sold.

Balentine LLC first reported a position in IONS in Q3 2016 and held it in 14 quarters. The position peaked at $87K in Q2 2017. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

Balentine LLC reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Balentine LLC sold 845 Ionis Pharmaceuticals shares in Q3 2020, an estimated $50K.
Balentine LLC first reported a position in Ionis Pharmaceuticals in Q3 2016 and held it in 14 quarters.
Balentine LLC's Ionis Pharmaceuticals position peaked at $87K in Q2 2017.
367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.